Biological effects of irradiating hepatocellular carcinoma cells by internal exposure with 125I-labeled 5-iodo-2'-deoxyuridine-chitosan drug loading nanoparticles.
In this study, the authors evaluate the biological effects of irradiation of hepatocellular carcinoma cells by internal exposure with (125)I-labeled 5-iodo-2'-deoxyuridine ((125)I-UdR)-chitosan drug loading nanoparticles ((125)I-UdR-CS-DLN). The authors observed that accumulation of nanoparticles was significantly (p<0.05) higher in hepatocellular carcinoma cells HepG2 than normal liver cells HL-7702 after treated with (125)I-UdR-CS-DLN for 30 minutes. Survival of HepG2 cells was significantly lower at (125)I-UdR-CS-DLN doses higher than 37 kBq/mL (more significant in the G1 phase and G2/M phase) than the HL-7702 cells. In addition, (125)I-UdR-CS-DLN induced a higher level of DNA double-strand breaks than (125)I-UdR, and HepG2 cells exhibited a lower level of DNA repair when compared with HL-7702 cells. In vivo animal experiments, TUNEL staining, after targeted treatment, showed that (125)I-UdR-CS-DLN induced significant cell apoptosis in rabbit hepatocellular tumors in situ than (125)I-UdR infusion at the same dose. In conclusion, hepatocellular carcinoma cells were significantly irradiated with (125)I-UdR-CS-DLN compared with (125)I-UdR, and (125)I-UdR-CS-DLN irradiation enhanced DNA damage, induced liver cancer cell apoptosis, and prevented DNA damage repair. However, evaluating the extent of damage and organ sparing in vivo should also be considered.
1 Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Medical College of Soochow University , Collaborative Innovation Center of Radiation Medicine, Jiangsu Higher Education Institutions, Suzhou, China .
Chen
C
Yang
Ran
R
Zhu
Jianmei
J
Wan
Bo
B
Jiang
Dayong
D
Zhou
Miaoli
M
Song
Fenju
F
Liu
D000818:Animals; D017209:Apoptosis / Q000528:radiation effects; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D048271:Chitosan / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004249:DNA Damage; D004260:DNA Repair; D056945:Hep G2 Cells; D006801:Humans; D007065:Idoxuridine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D008114:Liver Neoplasms, Experimental / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage*; D011817:Rabbits; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000493:pharmacokinetics
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D048271:Chitosan; D007065:Idoxuridine
125I-UdR-CS-DLN; biological effects; liver cancer; nanoparticles; passive targeting